Development and application of a blocking enzyme-linked immunosorbent assay (ELISA) to differentiate antibodies against live and inactivated porcine reproductive and respiratory syndrome virus 
Introduction
Porcine reproductive and respiratory syndrome virus (PRRSV) was first discovered in North America in 1987 and in Europe in 1990 (Andreyev et al., 1997; Benfield et al., 1992) . Porcine reproductive and respiratory syndrome (PRRS) continues to be a threat to the swine industry worldwide (Dea et al., 1992; Gao et al., 2004; Kapur et al., 1996) . Higher levels of viremia and virus excretion were observed in younger versus older pigs, and age-dependent variation in disease severity was observed in young pigs (Dea et al., 2000; Feng et al., 2008) . The unprecedented large-scale PRRS outbreaks in 2006 occurred over nearly half of China and involved 42,000,000 pigs, a matter of serious concern to the global swine industry and to the public health .
PRRSV is a small, enveloped RNA virus that belongs to the order Nidovirales, family Arteriviridae, genus Arterivirus, along with Equine arteritis virus, Lactate dehydrogenase-elevating virus of mice, and Simian hemorrhagic fever virus (den Boon et al., 1991; Ziebuhr et al., 2000) . The virus genome contains a 5′-cap and 3′-polyadenylate single-strand positive-sense RNA of approximately 15 kb. The viral genomic RNA contains at least nine open reading frames (ORFs), including ORF1a, ORF1b, ORF2a, ORF2b, ORFs3-7, and 5′-and 3′-untranslated regions (den Boon et al., 1991) . ORF1a and ORF1b comprise the majority of the 5′-terminal region of the genome, and encode the replicase polyprotein, which is considered to be auto-proteolytically cleaved into at least 13 nonstructural proteins (Nsps) assumed to be associated with the viral replication and transcription (Snijder et al., 1996) . Among the nonstructural genes of PRRSV, Nsp9 contained within ORF1b is the most conserved region of nidovirus genomes and encodes the RNA-dependent RNA polymerase (RdRP) (Kiss et al., 2006) .
Virus isolation, polymerase chain reaction (PCR), virus neutralization, indirect fluorescent antibody assay (IFA), and ELISA have been used to diagnose PRRSV infection (Ferrin et al., 2004) . Each method has its advantages, but diagnosis of PRRS has traditionally been based on the detection of antibodies (Abs) and/or the isolation of virus. An early diagnosis can often be achieved by the detection of PRRSV genomes by PCR or other nucleic acid tests (Christopher-Hennings et al., 1995) , while Abs are detected late in the course of disease. At present, serology still remains an important tool for the diagnosis of PRRS, and for retrospective epidemiological studies of outbreaks and prevalence. Several ELISA tests mostly based on the virus nucleocapsid (N) protein are commercially available to diagnose the disease (Jankova and Celer, 2012 ELISA kit, has become the industry standard for the detection of Abs against PRRSV because of high sensitivity, specificity, and repeatability (Chen et al., 2013; Jankova and Celer, 2012) . Although the kit has the ability to detect Abs against both types of PRRSV, it cannot distinguish Abs from live and inactivated PRRSV. In the case, the development and application of specific, sensitive, and validated serological methods to solve this problem is still important for the control of PRRS.
Infected animals, whether symptomatic or not, usually elicit Abs to both the PRRSV structural proteins (Sps) and Nsps (Johnson et al., 2007) . Since Nsps are exclusively synthesized during the PRRSV replication cycle and uninfected animals that had been vaccinated by inactivated virus preparations only elicit Abs to Sps (Paton et al., 2006) therefore the presence of anti-Nsp Abs in animal sera is a clear indication of virus activity.
In this study, the Nsp9 gene of American serotype of PRRSV was cloned and expressed to produce a novel monoclonal antibody (mAb). The aim of this study was to establish a sensitive and specific b-ELISA using a purified Nsp9 fusion protein antigen and the well-characterized 2D6 mAb and to evaluate the serological diagnostic potential for differentiation of post-infection and postvaccination antibodies vaccinated with the inactivated vaccine.
Results

Monoclonal antibodies against the Nsp9 protein
An 840 bp fragment representing the cDNA of Nsp9 was obtained by PCR (data not shown). The apparent molecular weight of the fusion protein was approximately 34 kDa by SDS-PAGE (Fig. 1) . A mAb was generated that recognized the Nsp9 fusion protein, named 2D6 (IgG1), which was produced at high titer by the hybridoma (640,000). The affinity constant for 2D6 was determined to be 1.8 Â 10 9 . The 2D6 mAb can specially recognize the Nsp9 protein by western blot (Fig. 2) . The IFA results showed that only cytoplasmic fluorescence was observed in PRRSVinfected MARC-145 cells (Fig. 3) . Additionally, 2D6 displayed specific detection of PRRS antigens in paraffin-embedded tissue sections from a pig infected by SW/JL/07 (Fig. 4 ). All these results suggested that 2D6 is able to detect PRRSV, and is likely to be suitable for use in a b-ELISA that requires specific Abs.
Characterization of Abs against Nsp9 and N proteins during disease
Changes in the Abs levels against Nsp9 and N proteins during PRRS were detected by the commercial kit and the b-ELISA. In Fig. 5 , inactivated virus did not induce the production of Nsp9 Abs, but could induce the production of Abs against the N proteins. Live virus can not only induce structural protein Abs, but also induce non-structural protein Abs, such as anti-Nsp9. The PI values recorded from PRRS reference antisera at a 1:5 dilution were between 31.7 and 72.2% (Fig. 6 ). All 25 positive sera showed that a recorded PI of 430% confirmed samples to be specific for PRRSV. Antisera prepared against five other related virus (CSFV, PPV, PRV, PCV, and JEV) displayed inhibition values o15.0%, and were therefore recorded as negative and deemed to not cross-react with PRRSV. The sensitivity of the b-ELISA showed that a 1:40 dilution of positive sera was the highest dilution, which showed a significant difference between positive and negative controls (P o0.05) (Fig. 7) .
Comparison of commercial and b-ELISA tests
A comparison of serological reactivity of both ELISA tests was performed on all groups of swine sera ( Table 1) . The results of 126 sera from PRRS free herds vaccinated with an inactivated vaccine confirmed the assumption that inactivated vaccine does not induce Nsp9 specific antibodies. For other 289 serum samples, 131 were determined to be negative by both methods (Tables 1 and 2) . Samples determined to be positive results by the b-ELISA were also positive by the commercial kit (n¼154), while some of the positive results detected by the kit were determined to be negative by the b-ELISA (n¼2). According to the clear immunization history of pig herbs, it can deduce that the b-ELISA method can differentiate Abs against live virus and inactivated vaccines. The b-ELISA within-plate %CV was 4.8, the %CV between plates in one run was 3.04, and the % CV between runs was 3.4. The b-ELISA antibody titers of these sera based on a 30% end-point were determined to be between 20 and 160. For 415 samples, the sensitivity for Nsp9 protein was calculated to be 98.7% and 98.5% of specificity when compared with the commercial kit (Table 3) .
Discussion
Along with the harm caused by PRRSV infection and the extensive application of vaccines, the differential diagnosis of PRRS is a major aspect of disease detection and control. Currently, serological diagnostic methods for the diagnosis of PRRS are more common, but serological methods to distinguish between natural infection and active immunization are not available. Therefore, to develop a diagnostic method that is able to distinguish between the vaccinated and naturally infected animals is important for disease prevention, diagnosis and treatment. MAbs can not only be used for the rapid and accurate diagnosis of pathogens but also be used for PRRS epidemiology and treatment of disease. Their application in diagnostic methods has proven their ability to detect animals that may not yet display clinical symptoms or detect a history of the previous exposure.
In the present study, the Nsp9 protein was chosen as the ELISA antigen because the homology of this region is highly conserved within PRRSV genomes of all American serotypes and relatively low compared with those European serotypes. With the 2D6 mAb specific to Nsp9, a b-ELISA method was developed because this method is superior as a screening test compared with the indirect ELISA: (i) the b-ELISA was better than the indirect ELISA in detecting Abs formed early after infection and superior to the indirect ELISA in detecting Abs at a late stage of infection; (ii) the b-ELISA gave higher Ab-units, while some sera with low Ab levels in the b-ELISA were negative in the indirect ELISA, indicating that the b-ELISA had a better ability to detect low levels of Abs; and (iii) it did not require a control antigen and therefore the double number of samples could be tested on each plate, compared to the indirect ELISA, resulting in a higher capacity and a cheaper test (Sorensen et al., 1997) . This assay exhibited high affinity for PRRSV with no cross-reactivity to common pig pathogens, such as CSFV, PPV, PRV, PCV, and JEV. To evaluate the sensitivity and specificity of the b-ELISA, 289 serum samples were examined. The results demonstrated similar sensitivity and specificity values for the b-ELISA and the commercial kit. As far as we know, this is the first mAb specific for Nsp9 which can be efficiently used to differentiate infected and vaccinated animals.
Vaccination is one of the most effective tools to control PRRS, although it does not prevent PRRSV infection. The inactivated vaccines are safety and generally commended to use for only healthy pig herds and breeding sows in China, while the live vaccines have proved much more efficacious. But the vaccine virus may shed, which is then transmitted in the field, complicating the problem of detecting infection with wild-type virus, both through virology and serology (Zimmerman et al., 2006) . Also, it has a rate of reversion to virulent strain. Despite the problems mentioned above, both inactivated and live vaccines against PRRSV have been developed and are widely used in China. Therefore, the b-ELISA is more useful for PRRS-negative farms, where pigs are vaccinated with inactivated PRRSV vaccines and thus differentiation between post-infection and post-vaccination Abs can provide important Table 3 Sensitivity and specificity of the commercial kit and b-ELISA. Sensitivity and specificity of the b-ELISA were calculated using the commercial kit as the reference method of detection for the swine sera (n¼ 289). Those of the commercial kit were determined using the b-ELISA as the reference assay. Sensitivity and specificity were calculated as follows:. insight into whether the circulation of field virus strains happens in these herds. One of the drawbacks of the study was that it is undetermined whether a positive result by b-ELISA was due to infection with natural virus or immunization with live vaccines. However, the b-ELISA will display its advantage for herbs immunized by the inactivated vaccines. In addition, it is also undetermined whether this method is able to differentiate Abs against both virus serotypes because there is no European-type PRRSV strain in our lab, although a few of European-PRRSVs have been described in China. In summary, the PRRS b-ELISA was proven to be appropriate for the diagnosis of PRRSV infections and continues to be an important tool for PRRS surveillance in pigs.
Materials and methods
Ethics statement
All animal research was conducted according to the experimental practices and standards approved by the Animal Welfare and Research Ethics Committee at Jilin University (Approval ID: 20100926-1).
Virus and sera
The American-type PRRSV, SW/JL/07, was isolated by our laboratory. 25 control positive sera from animals immunized by a live vaccine were identified as positive by a commercial kit based on the indirect ELISA (Lv Shiyuan, China) and 25 control negative sera were obtained from farms with no history of PRRS infection. The antisera to classical swine fever virus (CSFV), porcine parvovirus (PPV), porcine pseudorabies (PRV), porcine circovirus (PCV), and Japanese encephalitis virus (JEV) were prepared by our laboratory.
Cloning, expression, and purification of PRRSV Nsp9 polypeptide
The coding region for SW/JL/07 Nsp9 (GenBank: KF049009) was amplified by PCR from virus-derived cDNA using the forward primer, 5′-TCAAGCTTTGAGTGAGGTTGAGCTAAAAGAC-3′ and reverse primer, 5′-CGCTCGAGTCAGACAGTTTGCCAGTTTTCTCG-3′ that were engineered to contain Hind III and Xho I restriction sites (underlined), respectively. The Nsp9 PCR product was cloned into the pET-28a (+) vector, resulting in pET-28-Nsp9, which contained the fragment gene (coding for nucleotides 7819-8658) with a C-terminal extension, including a His-tag for protein purification. After verification by restriction analysis and nucleotide sequencing, the pET-28-Nsp9 was used to transform competent E. coli BL21 (DE3). Cultures were grown in Luria-Bertani medium containing 50 μg/mL kanamycin at 37 1C until cells reached an absorbance of 0.4 at a wavelength of 660 nm. Cells were induced with 1 mM isopropyl-β-D-thio-galactoside (IPTG) and grown for a further 4 h at 37 1C (shaking at 200 rpm). Cells were then harvested by centrifugation at 5000 Â g for 20 min at 4 1C and the resulting cell pellets were frozen at À 20 1C. For lysis, the cell pellets were resuspended in 20 mM Tris-HCl, 300 mM NaCl, 5 mM dithiothreitol (DTT), and 20 mM imidazole (pH 7.4). Cells were lysed by French press after the addition of glycerol to 10 v/v% and one complete EDTA-free protease inhibitor cocktail tablet. The Nsp9 fusion protein was purified by affinity chromatography using HisBind column according to manufacturer's instructions (GE, USA). The purity and concentration of the protein were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot.
Preparation of Nsp9 mAbs
The mAbs against the PRRSV Nsp9 polypeptide were generated using standard protocols (Kim et al., 2006) . Briefly, the Nsp9 fusion protein was emulsified (1:1, v/v) with Freund's complete adjuvant for primary immunizations and two female BALB/c mice were injected intraperitoneally with 100 mL of this emulsion. In the second and third injections, mice were immunized by the same method with 100 mL of antigen with Freund's incomplete adjuvant. Mice received a booster injection of 100 mg of the protein in PBS before cell fusion. The immune period was at the interval of two weeks, respectively. Three days after the final immunization, mice were sacrificed and spleens were aseptically removed for cell fusion. Hybridomas were cultured in RPMI-1640 medium containing 1 v/v% hypoxanthine-aminopterin-thymidine (Sigma, USA) in 96-well flat-bottom culture plates. The fused hybridoma clones were screened by an indirect ELISA for mAbs that recognized Nsp9 protein. The indirect ELISA protocol was performed as described previously for PRRSV (Wright et al., 1993) : (i) 100 μL PRRSV Nsp9 fusion protein was incubated at a predetermined dilution (1.5 μg/ mL) in coating buffer for overnight at 4 1C; (ii) 5% BSA blocking buffer for 1 h at 37 1C; (iii) supernatants of the cloned hybridoma (100 μL/well) were incubated for 1 h at 37 1C; (iv) goat anti-mouse IgG-HRP (1:5000) (Sigma, USA) in PBST was incubated for 1 h at 37 1C; (v) 100 μL OPD substrate was allowed to react for 20 min at room temperature before addition of 50 μL of 2 M H 2 SO 4 to stop the reaction. During the procedure, wells were washed five times with washing buffer after each step. Optical density (OD) readings were obtained at a wavelength of 490 nm.
Positive hybridomas were cloned by limiting dilution for three rounds, and the supernatants were used for further characterization. Ascites were produced by intraperitoneal injection of 5 Â 10 5 hybridoma cells into BALB/c mice that were treated with 0.5 mL/ mouse pristane (Sigma, USA). The subclass specificity of mAbs was determined using the IsoStrip mouse monoclonal antibody isotyping kit (Sigma, USA). Measurement of the affinity of the mAbs for Nsp9 was performed as previously described (Karlsson et al., 1991) .
Characterization of Nsp9-specific mAbs
The purified Nsp9 was subjected to electrophoresis on 12% SDS-PAGE gels. Western blot was used to analyze the reactivity between the bacterially-expressed His-tagged Nsp9 protein and porcine antisera to PRRSV and the prepared mAbs, respectively. Ten micrograms of the purified Nsp9 protein was subjected to SDS-PAGE, and then electrotransferred to polyvinylidene fluoride (PVDF) membrane (Millipore, USA). After blocking with 5% bovine serum albumin (BSA) for 1 h at 37 1C, the strips were incubated with porcine antisera to PRRSV (1:40) or the mAbs (1:20,000 for the acsite), and detected with rabbit anti-pig IgG-HRP (1:5000) (Sigma, USA) or goat anti-mouse IgG-HRP (1:5000) (Sigma, USA). After washing, the reaction was developed using 3,3′-diaminobenzidine (DAB) substrate (Sigma, USA) on the PVDF membrane for 1 min for color development.
In order to validate the binding potential of the mAbs with live virus, MARC-145 cells cultured on glass coverslips were infected with 200 μL of a 10 4 TCID 50 viral suspension of SW/JL/07 and incubated at 37 1C for 72 h in a humidified 5% CO 2 environment. Negative controls were prepared in an identical manner with cell culture medium instead of virus. Coverslips were removed and washed twice with PBST (pH 7.4). Cells were fixed in freshly prepared 3.7% paraformaldehyde in PBS followed by permeabilization with 0.2% Triton-X 100 (Sigma, USA) and processed with the mAbs and the supernatant of SP2/0 cell. The presence of antigen-antibody reaction was visualized by adding goat anti-mouse IgG-FITC (Sigma, USA). Cells were photographed using laser scanning confocal microscope (Olympus, Japan).
To further explore the diagnostic potential, the generated mAbs were used in immunohistochemistry (IHC) assays on formalinfixed, paraffin-embedded tissue sections obtained from SW/JL/07-infected pigs. Ten 5-week-old pigs were obtained from a PRRSVseronegative farm. Four pigs were intramuscularly injected with 10 5 TCID 50 /2 mL of SW/JL/07, the other three pigs were inoculated with the same dose of inactivated virus treated with 0.01% formalin, and another three pigs were a negative control. Three groups of pigs were kept separately. Venous blood was collected every 5 days and sera were obtained for detection of Abs using the commercial kit and the followed developed b-ELISA, respectively. One of four pigs infected with live virus was exsanguinated on day 7 postinoculation when obvious symptoms (high fever, anorexia, lethargy, and dyspnea) emerged and tissues were fixed in 10% formalin for 24 h and embedded in paraffin. Paraffin-embedded tissues were used for IHC as described before (Gomez-Laguna et al., 2009 ). In brief, duplicate sections of each tissue block were stained with the mAb specific for the Nsp9 of PRRSV at 1:1000 dilution overnight at 4 1C. Sections were treated with biotinylated secondary antibody (Vector Laboratories, USA) for 30 min at room temperature followed by washing in PBST. Stained sections were visualized using the NovaRED substrate kit (Vector Laboratories, USA). Sections were counterstained with Harris's hematoxylin, dehydrated, and mounted with Eukitt (Sigma, USA). Sections were visualized by light microscopy.
Development of a b-ELISA to differentiate Abs against live and inactivated viruses
The ELISA system used in this study was a modification of the b-ELISA as previously described (Sorensen et al., 2005) . The b-ELISA for detection of Abs to PRRSV was performed using the specific Nsp9 mAb. The optimal concentrations of mAb and secondary Ab were determined by the square experiment. The ELISA protocol was performed as follows: (i) 100 μL PRRSV Nsp9 fusion protein was incubated at a predetermined dilution (1.5 μg/mL) in coating buffer for 1 h at 37 1C; (ii) 5% BSA blocking buffer for 1 h at 37 1C; (iii) test sera, positive and negative serum controls were diluted 1:5 in blocking buffer (100 μL/well) and incubated for 2 h at 37 1C; (iv) the mAb was added to the plates (100 μL/well) at 1:10,000 dilution in PBST, and incubated for 1 h at 37 1C; (v) goat anti-mouse IgG-HRP (1:5000) in PBST was incubated for 1 h at 37 1C; and (vi) 100 μL OPD substrate was allowed to react for 20 min at room temperature before the addition of 50 μL of 2 M H 2 SO 4 to stop the reaction. During the procedure, wells were washed five times with washing buffer after each step. OD readings were obtained at a wavelength of 490 nm. Results were valid when the OD in negative control wells was over 0.8 OD units. A cut-off of percent inhibition (PI) was used to distinguish between negative and positive sera during the development of the test parameters. PI¼100 À [(OD490 of test sample/ median OD490 negative control) Â 100]. The cut-off value for the determination of positive samples was set by the average OD ratio of 25 fieldnegative sera and 25 positive sera determined by b-ELISA. A positive threshold for each assay was calculated using the receiver-operator characteristic (ROC) analysis. The OD value of negative control was the average OD of six negative controls.
To evaluate specificity of the b-ELISA, several antisera against different viruses (CSFV, PPV, PRV, PCV, and JEV) related to swine disease were evaluated as nonspecific serum samples. The sensitivity of the assay was determined by comparing the PI values obtained from a 1:5 dilution to 1:160 of 25 positive-control sera identified by the commercial kit. The commercial kit was used as a control. This b-ELISA was intended to detect the PRRSV Nsp9 Abs; therefore, if the Nsp9 Abs were detected, this would indicate the presence of an actively replicating PRRSV. In order to detect the b-ELISA titer, sera were diluted twofold. To further evaluate this assay, precision within and between runs was also examined. The same internal quality-control sera were used with the commercial kit and the b-ELISA.
Comparison of commercial and b-ELISA tests
A total of 415 serum samples were collected at random from animals with known immunization history of PRRS on six pig farms (Table 1 ). All these filed serum samples were tested for Abs to PRRSV using the commercial kit and the b-ELISA. To confirm the assumption that inactivated vaccine does not induce Nsp9 specific antibodies, 126 sera from herds vaccinated with an inactivated vaccine were evaluated by both tests. 289 sera (except for those against inactivated vaccines) were examined by both tests to evaluate diagnostic sensitivity and specificity of b-ELISA. The commercial kit was considered as the "standard" for this comparison.
Statistical analysis
The ROC analysis was used to determine the cut-off value that best differentiated negative and positive groups based on the value obtained in the area under the curve. Standard deviations (SD), percent coefficient of variation (%CV) values were calculated using the SPSS statistical software (version 13.0, SPSS Inc., Chicago, Illinois, USA). Statistical significance was defined as a P-value of o0.05.
